Showing 1561-1570 of 8883 results for "".
Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/series/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andAI for Patient Education and More
https://practicaldermatology.com/series/c-suite-chats/ai-for-patient-education-and-more/36239/Anastasia Georgievskaya, founder of Haut.AI, discusses the impact of new artificial intelligence tools such as a virtual skincare try-on that shows customers how sunscreen and its ingredients will impact skin over time.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Medical Dermatology Highlights
https://practicaldermatology.com/programs/practical-dermatology/medical-dermatology-highlights/35889/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, summarizes the various medical dermatology sessions he presented at Music City SCALE 2025.Seborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fDr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Leading Dermatologists Summarize Maui Derm Presentations
https://practicaldermatology.com/series/dermwire-tv/leading-dermatologists-summarize-maui-derm-presentations/32839/In this week's DermwireTV, top thought leaders provide a summary of their presentations at Maui Derm; a new analysis examines a link between hidradenitis suppurativa genetics and coronary artery disease risk; and the president of Castle Biosciences joins us for this week's C-Suite Chats fJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseCanadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.